Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Tuesday, September 24, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

CARY, N.C. and BASEL, Switzerland, Sept. 24, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will present clinical safety, pharmacokinetic and biomarker data from two Phase 1 clinical studies

of rodatristat ethyl at the 29th International Congress of the European Respiratory Society (ERS) being held September 28th - October 2nd in Madrid, Spain.

The poster presentation, titled "Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH," will provide evidence of a favorable safety and tolerability profile for rodatristat ethyl at doses required to achieve therapeutically meaningful peripheral serotonin reduction. The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.

Rodatristat is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin. An established body of scientific evidence supports dysregulated peripheral serotonin production as a trigger of aberrant proliferation and constriction of the smooth muscle cells in the wall of the pulmonary arteries, leading to restricted blood flow in patients with pulmonary arterial hypertension (PAH).* By lowering circulating serotonin levels, it is believed that rodatristat may halt and even reverse the pathology of diseases that are driven by excessive serotonin production, such as PAH or idiopathic pulmonary fibrosis (IPF). Altavant is currently evaluating rodatristat ethyl in the ELEVATE 1 proof-of-concept Phase 2a study in patients with PAH.

About Altavant SciencesAltavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases with an initial focus on pulmonary arterial hypertension (PAH). Altavant's lead candidate, rodatristat ethyl, is a prodrug for rodatristat, a tryptophan hydroxylase (TPH) inhibitor that has reduced peripheral production of serotonin in healthy subjects, and may thereby lower circulating serotonin levels in diseases where excessive production of the hormone has been implicated in their pathogenesis - including PAH, certain types of cancer, gastrointestinal disorders, fibrosis and inflammation. Rodatristat ethyl is currently being evaluated in the ELEVATE 1 Phase 2 Study for patients with PAH. For more information, please visit

About Roivant PharmaRoivant Pharma is the biopharmaceutical business unit of Roivant Sciences. Roivant Pharma is focused on end-to-end biopharmaceutical company creation, launch, and oversight. Roivant Pharma companies include Altavant, Aruvant, Axovant, Dermavant, Enzyvant, Genevant, Immunovant, Metavant, Myovant, Respivant, Urovant, and Arbutus.

About Roivant SciencesRoivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. Roivant does this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit  

Contact: Chelcie Lister, THRUST Strategic Communications

* M.R. MacLean et al; Pulmonary Circulation 2018; 8(2) 1–9


Cision View original content:

SOURCE Altavant Sciences

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store